Background: Regulatory T-cells (Tregs) play an important role in escape of tumour cells from
immune surveillance and their presence in the tumour microenvironment and presumably
their increase in circulation reflects the level of tumour immunosuppression. The
anti-cancer effect of anti-VEGF bevacizumab is conferred not only by its anti-angiogenic
but also by its immunomodulatory effect. We have observed that primary tumour sidedness
is an important predictor of the clinical outcome of the 1st anti-VEGF therapy of
metastatic CRC where patients with right-sided tumours have poor prognosis irrespective
of KRAS status and patients with left-sided colon carcinoma benefited from anti-VEGF
therapy specifically those with wt KRAS (1). Our goal was to investigate whether circulating
Treg level in mCRC patients i/ differs according to primary tumour sidedness, ii/
is related to tumour KRAS status, iii/ predicts anti-VEGF treatment outcome.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
A2
Identification
Copyright
© 2018 Published by Elsevier Inc.
